Sunday, September 24, 2017 12:22:02 AM
420m EV
With a fully funded Phase 1 trial of NB1222/NB1111 and then positive results, we would be Off to the races. Look at $ZYNE at its Peak , much higher
And Look at GW. SPent a Lot of time on their first drug that WILL NEVER get approved in the USA as a medicine. Maybe one day as a rec product. And now a new Drug in Phase 3 trials, when asked about the science of your manufacturing you give toss a word salad and conclude with 'sorry about unscientific answer', and now doubt about whether the benefit of CBD is directly from the molecule or an interaction with other epilepsy drugs.
Still 1B market cap.
I have them Right between the eyes, whether they know it or not
And I hope $ZYNE goes higher but some People are probably pretty mad at Management
I'm not short either and wish them Good luck
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM